Biogen (BIIB) Share-based Compensation (2009 - 2026)

Biogen has reported Share-based Compensation for 18 years, with the latest figure at $77.4 million in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 3.34% year-over-year to $77.4 million in Q2 2026; TTM through Jun 2026 was $296.3 million, a 2.44% decrease from a year earlier, with the FY2025 full-year figure at $290.8 million, changed 0.14% from the prior year.
• Share-based Compensation was $77.4 million for Q2 2026 at Biogen, down from $84.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $84.0 million in Q1 2026, with the low at $54.9 million in Q4 2023.
• Average Share-based Compensation over 5 years is $70.1 million, with a median of $72.1 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation surged 36.79% in 2024, then retreated 20.64% in 2025.
• Over 5 years, Share-based Compensation stood at $67.2 million in 2022, then slipped by 18.3% to $54.9 million in 2023, then soared by 36.79% to $75.1 million in 2024, then fell by 20.64% to $59.6 million in 2025, then grew by 29.87% to $77.4 million in 2026.
• The last three Share-based Compensation figures came in at $77.4 million (Q2 2026), $84.0 million (Q1 2026), and $59.6 million (Q4 2025), per Business Quant data.